
Best Practices Treatment Guideline for Depression


Based on 2010 APA guidelines and NeuroStar TMS Therapy® indication for use.1

| First Line Treatment Attempts NEXT TRIAL | TMS Non-Invas Non-Syste | sive | ☐ Scal | 1S Side Effects o Pain or Discomfort eatment Site | |
|--|--|----------------------|--------------------|---|----------------------------|
| SSRI | Single Antidepressant Medication Maintenance | | | | |
| Celexa® (citalopram) Lexapro® (escitalopram) Prozac® (fluoxetine) Luvox® (fluvoxamine) Paxil® (paroxetine) Zoloft® (sertraline) | Antidepres Switch Non MAOI MAOIs/TCA On-going Multi 2 Mont | Class TRIA As | Sti pressant Me | mentation rategies Months | Antipsychotic Augmentation |
| DNRI | Most com | mon side effec | | Orug Side Effects ressant medication label | s (5% and 2x placebo) |
| \\\alpha\ \text{lb.u.twin}\ \text{R}\ \lambda\ \text{lb.u.twin}\ \text{R}\ \text{lb.u.twin}\ \text{lb.u.twin}\ \text{lb.u.twin}\ \text{R}\ \text{lb.u.twin}\ | | ☐ Nervous | | ☐ Weakness | Abnormal Ejaculation |
| Wellbutrin® (bupropion) | Weight Gain | | | | |
| SNRI Other Treatments | ☐ Constipation | Anxiety | | ☐ Dry Mouth | ☐ Impotence |
| | | _ | d Appetite | ☐ Dry Mouth ☐ Dizziness | ☐ Impotence ☐ Sweating |
| SNRI Other Treatments Cymbalta® Edronax® | ☐ Constipation | ☐ Anxiety ☐ Increase | d Appetite | | |

1. Adapted from Star*D Study

As Medication Increases, So Can Side Effects and the Potential for Treatment Failure





NeuroStarTMSTherapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.

In clinical trials, patients treated with active NeuroStarTMS Therapy experienced an average reduction in their depression symptom score of 22.1% compared to a 9% reduction in patients receiving inactive treatment.

In an open-label clinical trial, most like real world clinical practice, I out of 2 patients treated with NeuroStarTMSTherapy® experienced significant improvement in depression symptoms.

I out of 3 experienced complete symptom relief at the end of six weeks.

NeuroStarTMSThearpy is available by prescription only. For full prescribing and safety information, please visit: www.NeuroStar.com

1. Trivedi, M. H., A. J. Rush, et al. (2006). "Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in STAR*D Implications for Clinical Practice." Am J Psychiatry 163(1): 28-40 2. Rush AJ, et. al.: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905–1917 3. Fava, M.,et. al. (2006). "A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A Star*D Report." Am J Psychiatry 163(7): 1161-1172 4. McGrath, P. J., et al. (2006). "Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report." Am J Psychiatry 163(9): 1531-1541

NeuroStar, Celexa, Lexapro, Prozac, Luvox, Paxil, Zoloft, Wellbutrin, Cymbalta, Effexor, Pristiq, Edronax, and Remeron are registered trademarks of their manufacturer.

© 2010 Neuronetics, Inc., Malvern, PA 52-60043-000 Rev C